Alpha1-Proteinase Inhibitor (Human), ZEMAIRA® is indicated to raise the plasma level of alpha1-proteinase inhibitor (A1-PI) in patients with A1-PI deficiency and related emphysema.
Alpha1-Proteinase Inhibitor (Human), ZEMAIRA® is indicated to raise the plasma level of alpha1-proteinase inhibitor (A1-PI) in patients with A1-PI deficiency and related emphysema.
Dosing information Usual Adult Dose for Alpha-1 Proteinase Inhibitor Deficiency: 60 mg/kg intravenously once a week Comments: -Dose ranging studies using efficacy endpoints have not been performed. Use: Chronic augmentation and maintenance therapy in adults with clinical evidence of emphysema due to ...
在欧洲,Zemaira以品牌名Respreeza®上市销售。 原文出处:CSL Behring Delivers on its Continued Commitment to Alpha 1 Patients with FDA Approval of Convenient Single-Vial Dosing for ZEMAIRA® [Alpha1-Proteinase Inhibitor (Human)] 原标题:治疗α1抗胰蛋白酶缺乏症!杰特贝林Zemaira(α1蛋白酶抑制剂[人])...
Benefits of ZEMAIRA Choose an Alpha-1 therapy that offers the convenience patients want and the efficacy and purity you can trust. LEARN MORE Stay Updated with ZEMAIRA Sign up to get the latest updates about A1AT and ZEMAIRA sent straight to you. ...
Dosing & Uses AdultPediatric Dosage Forms & Strengths lyphilized powder for reconstitution 0.5g/vial (Aralast NP) 1g/vial (Aralast NP, Zemaira) 4g/vial (Zemaira) 5g/vial (Zemaira) ready-to-use IV solution 1g/50mL (Glassia) 1g/20mL (Prolastin C) Alpha-1 Antitrypsin Deficiency Indicated ...